Arkolith/Insider Trading/NKTR/Form 4

Zalevsky Jonathan

Chief R&D OfficerNEKTAR THERAPEUTICS (NKTR) · full profile →Form 4 · filed Dec 17, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 13, 2024Grant(A)135K—$0378K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 13, 2024Grant(A)375K—$0375K
Dec 13, 2024Grant(A)270K—$0270K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-137545) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML